In addition, while Dasatinib treatment was able to effectively inhibit p‐Lyn and p‐Src expression in HCC cells, the antineoplastic activity of Dasatinib was not correlated to c‐Myc, p‐Lyn, or p‐Src levels. This evidence concerns the gene SRC and hepatocellular carcinoma.